GB9715894D0 - Heterocyclic derivatives - Google Patents

Heterocyclic derivatives

Info

Publication number
GB9715894D0
GB9715894D0 GBGB9715894.3A GB9715894A GB9715894D0 GB 9715894 D0 GB9715894 D0 GB 9715894D0 GB 9715894 A GB9715894 A GB 9715894A GB 9715894 D0 GB9715894 D0 GB 9715894D0
Authority
GB
United Kingdom
Prior art keywords
heterocyclic derivatives
relates
antithrombotic
anticoagulant
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9715894.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Priority to GBGB9715894.3A priority Critical patent/GB9715894D0/en
Publication of GB9715894D0 publication Critical patent/GB9715894D0/en
Priority to JP2000505130A priority patent/JP2001512103A/ja
Priority to RU2000104829/04A priority patent/RU2225404C2/ru
Priority to AU84557/98A priority patent/AU754747B2/en
Priority to PCT/GB1998/002210 priority patent/WO1999006371A1/en
Priority to HU0002528A priority patent/HUP0002528A3/hu
Priority to IL13351698A priority patent/IL133516A0/xx
Priority to BR9811055-1A priority patent/BR9811055A/pt
Priority to PT98935208T priority patent/PT1000033E/pt
Priority to CA002295945A priority patent/CA2295945A1/en
Priority to SK127-2000A priority patent/SK1272000A3/sk
Priority to AT98935208T priority patent/ATE266007T1/de
Priority to TR2000/00223T priority patent/TR200000223T2/xx
Priority to ES98935208T priority patent/ES2219894T3/es
Priority to US09/463,625 priority patent/US6458793B1/en
Priority to PL98338355A priority patent/PL338355A1/xx
Priority to CN98807641A priority patent/CN1265098A/zh
Priority to DE69823665T priority patent/DE69823665T2/de
Priority to EP98935208A priority patent/EP1000033B1/en
Priority to DK98935208T priority patent/DK1000033T3/da
Priority to NZ501778A priority patent/NZ501778A/en
Priority to KR1020007000678A priority patent/KR20010022108A/ko
Priority to EP03018010A priority patent/EP1367054A1/en
Priority to NO20000448A priority patent/NO317419B1/no
Priority to US10/180,337 priority patent/US20020193375A1/en
Priority to NO20040520A priority patent/NO20040520L/no
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
GBGB9715894.3A 1997-07-29 1997-07-29 Heterocyclic derivatives Pending GB9715894D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB9715894.3A GB9715894D0 (en) 1997-07-29 1997-07-29 Heterocyclic derivatives
EP03018010A EP1367054A1 (en) 1997-07-29 1998-07-23 Heterocyclic factor Xa inhibitors
TR2000/00223T TR200000223T2 (tr) 1997-07-29 1998-07-23 XA faktörünü engelleyen heterosiklik türevler
US09/463,625 US6458793B1 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor Xa
AU84557/98A AU754747B2 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor XA
PCT/GB1998/002210 WO1999006371A1 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa
HU0002528A HUP0002528A3 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa
IL13351698A IL133516A0 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa
BR9811055-1A BR9811055A (pt) 1997-07-29 1998-07-23 Composto , uso do mesmo, composição farmacêutica, e, processo para tratamento de doença ou condição médica mediada pelo fator xa
PT98935208T PT1000033E (pt) 1997-07-29 1998-07-23 Derivados heterociclicos que inibem o factor xa
CA002295945A CA2295945A1 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa
SK127-2000A SK1272000A3 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa
AT98935208T ATE266007T1 (de) 1997-07-29 1998-07-23 Heterocyclische verbindungen als faktor xa inhibitoren
JP2000505130A JP2001512103A (ja) 1997-07-29 1998-07-23 第ｘａ因子を阻害する複素環誘導体
ES98935208T ES2219894T3 (es) 1997-07-29 1998-07-23 Derivados heterociclicos que inhiben el factor xa.
RU2000104829/04A RU2225404C2 (ru) 1997-07-29 1998-07-23 ПРОИЗВОДНЫЕ ПИПЕРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ФАКТОРА Хa
PL98338355A PL338355A1 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives capable to inhibit the factor xa
CN98807641A CN1265098A (zh) 1997-07-29 1998-07-23 抑制因子xa的杂环衍生物
DE69823665T DE69823665T2 (de) 1997-07-29 1998-07-23 Heterocyclische verbindungen als faktor xa inhibitoren
EP98935208A EP1000033B1 (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor xa
DK98935208T DK1000033T3 (da) 1997-07-29 1998-07-23 Heterocykliske derivater, som inhiberer Faktor Xa
NZ501778A NZ501778A (en) 1997-07-29 1998-07-23 Heterocyclic derivatives which inhibit factor Xa
KR1020007000678A KR20010022108A (ko) 1997-07-29 1998-07-23 인자 ｘａ를 억제하는 헤테로사이클 유도체
NO20000448A NO317419B1 (no) 1997-07-29 2000-01-28 Heterocykliske derivater som inhiberer faktor XA
US10/180,337 US20020193375A1 (en) 1997-07-29 2002-06-27 Heterocyclic derivatives which inhibit factor Xa
NO20040520A NO20040520L (no) 1997-07-29 2004-02-05 Heterocykliske derivater som inhiberer faktor XA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9715894.3A GB9715894D0 (en) 1997-07-29 1997-07-29 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
GB9715894D0 true GB9715894D0 (en) 1997-10-01

Family

ID=10816578

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9715894.3A Pending GB9715894D0 (en) 1997-07-29 1997-07-29 Heterocyclic derivatives

Country Status (23)

Country Link
US (2) US6458793B1 (cg-RX-API-DMAC7.html)
EP (2) EP1367054A1 (cg-RX-API-DMAC7.html)
JP (1) JP2001512103A (cg-RX-API-DMAC7.html)
KR (1) KR20010022108A (cg-RX-API-DMAC7.html)
CN (1) CN1265098A (cg-RX-API-DMAC7.html)
AT (1) ATE266007T1 (cg-RX-API-DMAC7.html)
AU (1) AU754747B2 (cg-RX-API-DMAC7.html)
BR (1) BR9811055A (cg-RX-API-DMAC7.html)
CA (1) CA2295945A1 (cg-RX-API-DMAC7.html)
DE (1) DE69823665T2 (cg-RX-API-DMAC7.html)
DK (1) DK1000033T3 (cg-RX-API-DMAC7.html)
ES (1) ES2219894T3 (cg-RX-API-DMAC7.html)
GB (1) GB9715894D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0002528A3 (cg-RX-API-DMAC7.html)
IL (1) IL133516A0 (cg-RX-API-DMAC7.html)
NO (2) NO317419B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ501778A (cg-RX-API-DMAC7.html)
PL (1) PL338355A1 (cg-RX-API-DMAC7.html)
PT (1) PT1000033E (cg-RX-API-DMAC7.html)
RU (1) RU2225404C2 (cg-RX-API-DMAC7.html)
SK (1) SK1272000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200000223T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999006371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
DE69921994T2 (de) 1998-05-02 2005-12-01 Astrazeneca Ab Heterozyklische verbindungen mit faktor xa hemmender wirkung
GB9809349D0 (en) * 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
GB9902989D0 (en) * 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
DE10137163A1 (de) 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
RS66218B1 (sr) 2019-07-01 2024-12-31 Tonix Pharma Ltd Anti-cd154 antitela i njihove upotrebe
WO2022150452A1 (en) 2021-01-06 2022-07-14 Seth Lederman Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905526D0 (en) * 1989-03-10 1989-04-19 Fujisawa Pharmaceutical Co N-containing heterocyclic compounds,processes for the preparation thereof and composition comprising the same
US5541330A (en) * 1991-12-10 1996-07-30 Eastman Kodak Company Ion-sensitive compounds
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
UA56197C2 (uk) * 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні

Also Published As

Publication number Publication date
NO20000448L (no) 2000-03-16
NO20000448D0 (no) 2000-01-28
DE69823665T2 (de) 2005-04-28
KR20010022108A (ko) 2001-03-15
EP1000033A1 (en) 2000-05-17
AU754747B2 (en) 2002-11-21
ATE266007T1 (de) 2004-05-15
CA2295945A1 (en) 1999-02-11
NO20040520L (no) 2004-02-05
EP1367054A1 (en) 2003-12-03
BR9811055A (pt) 2000-09-05
RU2225404C2 (ru) 2004-03-10
PT1000033E (pt) 2004-08-31
EP1000033B1 (en) 2004-05-06
IL133516A0 (en) 2001-04-30
ES2219894T3 (es) 2004-12-01
TR200000223T2 (tr) 2000-07-21
AU8455798A (en) 1999-02-22
HUP0002528A3 (en) 2002-09-30
DE69823665D1 (de) 2004-06-09
CN1265098A (zh) 2000-08-30
US6458793B1 (en) 2002-10-01
US20020193375A1 (en) 2002-12-19
HUP0002528A2 (hu) 2001-06-28
SK1272000A3 (en) 2000-06-12
JP2001512103A (ja) 2001-08-21
PL338355A1 (en) 2000-10-23
DK1000033T3 (da) 2004-08-02
WO1999006371A1 (en) 1999-02-11
NZ501778A (en) 2001-09-28
NO317419B1 (no) 2004-10-25

Similar Documents

Publication Publication Date Title
GB9715894D0 (en) Heterocyclic derivatives
MY124122A (en) Heterocyclic derivatives
IL139406A0 (en) Heterocyclic derivatives which inhibit factor xa
MY139102A (en) Substituted n-aryl heterocycles, process for their preparation and their use as medicaments
GB9809349D0 (en) Heterocyclic derivatives
NO20010940L (no) TAN-1057 derivater
GB9902989D0 (en) Heterocyclic derivatives
WO2003024996A3 (de) Antibakterielle makrozyklen
PT952157E (pt) Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina